BioNTech and Roche subsidiary Genentech are discontinuing testing of their jointly developed personalized cancer vaccine in colorectal cancer patients. The companies were testing the mRNA vaccine ...

The firm said it will stop enrolling a late-stage trial in blood cancers to prioritize a preclinical in vivo T-cell receptor program in solid tumors.

For patients with microsatellite instability of mismatch repair deficiency, the final decision cements access to the drug, which was previously offered provisionally.

The approval was based on results from the Phase III HERIZON-GEA-01 trial, which compared the two Ziihera combos to Herceptin plus chemo.

The firm hopes to expand Revtorpyk's approval to HR-positive, HER2-negative breast cancer patients regardless of PIK3CA status.

The firm is testing the next dose level of RV-01 in a Phase I/IIa study after clearance from a safety and monitoring committee.

The study partially fulfills a goal set in the company's latest strategic plan that emphasizes late-stage and pivotal trials.

Three years after announcing the trial, the company dosed the first patient with the therapy, which targets kappa myeloma antigens.

The loans can be converted to stock if certain milestones are reached, or Moderna is required to pay investors back by 2032.

This marks the company's first study in POLG-mediated primary mitochondrial disease, after completing a Phase I trial in healthy volunteers.

Regulators approved the FGFR1/2/3 inhibitor based on data showing a 42.5 percent objective response rate and 16.6 months of median overall survival.